Abbott (ABT) Receives FDA's Approval for the TriClip TEER System
https://www.zacks.com/stock/news/2251212/abbott-abt-receives-fda-s-approval-for-the-triclip-teer-system?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251212
Apr 05, 2024 - Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
0
Here's Why You Should Retain Penumbra (PEN) Stock for Now
https://www.zacks.com/stock/news/2252020/here-s-why-you-should-retain-penumbra-pen-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252020
Apr 08, 2024 - Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.
0
IM Cannabis (IMCC) Expands Business in Germany With New Alliance
https://www.zacks.com/stock/news/2251935/im-cannabis-imcc-expands-business-in-germany-with-new-alliance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251935
Apr 08, 2024 - The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
0
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
https://www.zacks.com/stock/news/2252692/here-s-why-you-should-retain-myriad-genetics-mygn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252692
Apr 09, 2024 - Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
0
Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail
https://www.zacks.com/stock/news/2254645/hologic-s-holx-new-launches-aid-macroeconomic-issues-ail?cid=CS-ZC-FT-analyst_blog|zer_report_update-2254645
Apr 12, 2024 - Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.
0
Here's What Key Metrics Tell Us About Stryker (SYK) Q1 Earnings
https://www.zacks.com/stock/news/2265491/here-s-what-key-metrics-tell-us-about-stryker-syk-q1-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2265491
Apr 30, 2024 - The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow
https://www.zacks.com/stock/news/2223473/zimmer-biomet-zbh-q4-earnings-top-estimates-margins-grow?cid=CS-ZC-FT-analyst_blog|earnings_article-2223473
Feb 08, 2024 - Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER in the fourth quarter.
0
Here's Why You Should Retain CVS Health (CVS) Stock for Now
https://www.zacks.com/stock/news/2226281/here-s-why-you-should-retain-cvs-health-cvs-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2226281
Feb 14, 2024 - Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.
0
Edwards (EW) Gains From Balanced Core Growth and New Launches
https://www.zacks.com/stock/news/2226830/edwards-ew-gains-from-balanced-core-growth-and-new-launches?cid=CS-ZC-FT-analyst_blog|zer_report_update-2226830
Feb 15, 2024 - Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.
0
Here's Why You Should Retain Insulet (PODD) Stock for Now
https://www.zacks.com/stock/news/2227404/here-s-why-you-should-retain-insulet-podd-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2227404
Feb 16, 2024 - The huge success of Omnipod 5 boosts investors' confidence in Insulet (PODD).
0